Methotrexat Ebewe (Methotrexate Disodium)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to produce tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize DNA, RNA, and proteins efficiently. This halts the proliferation of rapidly dividing cells such as cancer cells and activated immune cells, reducing disease activity.

The specific dose of Methotrexat Ebewe is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Only a qualified healthcare professional can set the appropriate dosing regimen.

Methotrexat Ebewe is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Methotrexate is a widely used folate antagonist with a well‑established efficacy and safety profile. Compared with newer agents such as pemetrexed or leflunomide, methotrexate is generally less expensive and has extensive clinical experience, though individual response and toxicity may vary.

Methotrexat Ebewe should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain stability and sterility.

Methotrexat Ebewe is supplied as a sterile injectable solution and can be given intramuscularly, intravenously or subcutaneously, depending on the clinical indication and physician’s judgment. Administration is performed by a qualified healthcare professional under aseptic conditions.

The most serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and life‑threatening infections. Patients should be monitored regularly for liver enzymes, lung function and blood counts to detect these complications early.

Methotrexat Ebewe should not be used by pregnant women, individuals with severe renal or hepatic impairment, patients with known hypersensitivity to methotrexate or its excipients, and those receiving live vaccines. It is also contraindicated in patients with active infections that could be worsened by immunosuppression.